AnaptysBio (ANAB) Stock Forecast & Price Target

Compare

579 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANAB Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

AnaptysBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANAB Stock 12 Month Forecast

Average Price Target

$50.86

▲(112.80%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $50.86 with a high forecast of $90.00 and a low forecast of $25.00. The average price target represents a 112.80% change from the last price of $23.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","91":"$91","31.75":"$31.8","51.5":"$51.5","71.25":"$71.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,31.75,51.5,71.25,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.86,27.10153846153846,32.34307692307692,37.58461538461539,42.826153846153844,48.06769230769231,53.30923076923077,58.550769230769234,63.792307692307695,69.03384615384616,74.27538461538461,79.51692307692308,84.75846153846155,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.86,24.09076923076923,26.32153846153846,28.552307692307693,30.783076923076923,33.01384615384615,35.244615384615386,37.47538461538461,39.706153846153846,41.93692307692308,44.167692307692306,46.39846153846154,48.62923076923077,{"y":50.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.86,22.10153846153846,22.34307692307692,22.584615384615383,22.826153846153847,23.067692307692308,23.30923076923077,23.55076923076923,23.79230769230769,24.033846153846152,24.275384615384617,24.516923076923078,24.75846153846154,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.94,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.81,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.86,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$50.86

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Hold

4.60%

Upside

Reiterated

06/07/25

The overall stock score reflects a mix of strong technical momentum and promising trial results against a backdrop of financial and valuation challenges. While the technical indicators and positive trial results are encouraging, the company's current financial performance and negative valuation metrics dampen the overall score.

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/12/25

Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), CureVac (NASDAQ: CVAC) and AnaptysBio (NASDAQ: ANAB)

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/11/25

AnaptysBio shares are undervalued, says JPMorganAnaptysBio shares are undervalued, says JPMorgan

Joon LeeTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/04/25

AnaptysBio (ANAB) Receives a Hold from Truist Financial

Yasmeen RahimiPiper Sandler

Piper Sandler

$57

Buy

138.49%

Upside

Reiterated

06/04/25

Piper Sandler Sticks to Their Buy Rating for AnaptysBio (ANAB)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$55

Buy

130.13%

Upside

Reiterated

06/04/25

Stifel Nicolaus Remains a Buy on AnaptysBio (ANAB)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$22→$38

Buy

59.00%

Upside

Upgraded

06/04/25

AnaptysBio's Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/04/25

AnaptysBio (ANAB) Gets a Buy from TD Cowen

Derek ArchilaWells Fargo

Wells Fargo

$51

Buy

113.39%

Upside

Assigned

06/03/25

Promising Potential of AnaptysBio's Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook

Yatin SunejaGuggenheim

Guggenheim

$54→$90

Buy

276.57%

Upside

Reiterated

05/28/25

Guggenheim Sticks to Its Buy Rating for AnaptysBio (ANAB)

Andy ChenWolfe Research

Wolfe Research

$25

Buy

4.60%

Upside

Reiterated

05/21/25

Wolfe Research: Bullish long-term on ANABWolfe Research analyst Andy Chen reiterated an Outperform rating and $25.00 price target on AnaptysBio (NASDAQ: ANAB).

David NierengartenWedbush

Wedbush

$40

Buy

67.36%

Upside

Reiterated

05/06/25

AnaptysBio (ANAB) Receives a Buy from Wedbush

Julian HarrisonBTIG

BTIG

―

Hold

―

Downgraded

12/02/24

AnaptysBio downgraded to Neutral from Buy at BTIGAnaptysBio downgraded to Neutral from Buy at BTIG

Eliana MerleUBS

UBS

$23→$33

Hold

38.08%

Upside

Reiterated

10/30/24

AnaptysBio (ANAB) PT Raised to $33 at UBSUBS analyst Eliana Merle raised the price target on AnaptysBio (NASDAQ: ANAB) to $33.00 (from $23.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Hold

4.60%

Upside

Reiterated

06/07/25

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/12/25

Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), CureVac (NASDAQ: CVAC) and AnaptysBio (NASDAQ: ANAB)

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/11/25

AnaptysBio shares are undervalued, says JPMorganAnaptysBio shares are undervalued, says JPMorgan

Joon LeeTruist Financial

Truist Financial

―

Hold

―

Reiterated

06/04/25

AnaptysBio (ANAB) Receives a Hold from Truist Financial

Yasmeen RahimiPiper Sandler

Piper Sandler

$57

Buy

138.49%

Upside

Reiterated

06/04/25

Piper Sandler Sticks to Their Buy Rating for AnaptysBio (ANAB)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$55

Buy

130.13%

Upside

Reiterated

06/04/25

Stifel Nicolaus Remains a Buy on AnaptysBio (ANAB)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$22→$38

Buy

59.00%

Upside

Upgraded

06/04/25

AnaptysBio's Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/04/25

AnaptysBio (ANAB) Gets a Buy from TD Cowen

Derek ArchilaWells Fargo

Wells Fargo

$51

Buy

113.39%

Upside

Assigned

06/03/25

Promising Potential of AnaptysBio's Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook

Yatin SunejaGuggenheim

Guggenheim

$54→$90

Buy

276.57%

Upside

Reiterated

05/28/25

Guggenheim Sticks to Its Buy Rating for AnaptysBio (ANAB)

Andy ChenWolfe Research

Wolfe Research

$25

Buy

4.60%

Upside

Reiterated

05/21/25

Wolfe Research: Bullish long-term on ANABWolfe Research analyst Andy Chen reiterated an Outperform rating and $25.00 price target on AnaptysBio (NASDAQ: ANAB).

David NierengartenWedbush

Wedbush

$40

Buy

67.36%

Upside

Reiterated

05/06/25

AnaptysBio (ANAB) Receives a Buy from Wedbush

Julian HarrisonBTIG

BTIG

―

Hold

―

Downgraded

12/02/24

AnaptysBio downgraded to Neutral from Buy at BTIGAnaptysBio downgraded to Neutral from Buy at BTIG

Eliana MerleUBS

UBS

$23→$33

Hold

38.08%

Upside

Reiterated

10/30/24

AnaptysBio (ANAB) PT Raised to $33 at UBSUBS analyst Eliana Merle raised the price target on AnaptysBio (NASDAQ: ANAB) to $33.00 (from $23.00) while maintaining a Neutral rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

1 Month

xxx

Success Rate

10/13 ratings generated profit

Average Return

+5.28%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +5.28% per trade.

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+9.98%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +9.98% per trade.

1 Year

Joseph ThomeTD Cowen

Success Rate

8/12 ratings generated profit

Average Return

+9.97%

reiterated a buy rating 14 days ago

Copying Joseph Thome's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +9.97% per trade.

2 Years

xxx

Success Rate

8/12 ratings generated profit

Average Return

+12.26%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +12.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANAB Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ANAB has received 21 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the past 3 months is 50.86.

Each month's total comprises the sum of three months' worth of ratings.

ANAB Financial Forecast

ANAB Earnings Forecast

Next quarter’s earnings estimate for ANAB is -$1.52 with a range of -$1.85 to -$0.89. The previous quarter’s EPS was -$1.28. ANAB beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year ANAB has Outperformed its overall industry.

ANAB Sales Forecast

Next quarter’s sales forecast for ANAB is $11.51M with a range of $0.00 to $23.90M. The previous quarter’s sales results were $27.77M. ANAB beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ANAB has Outperformed its overall industry.

ANAB Stock Forecast FAQ

What is ANAB’s average 12-month price target, according to analysts?

Based on analyst ratings, AnaptysBio’s 12-month average price target is 50.86.

What is ANAB’s upside potential, based on the analysts’ average price target?

AnaptysBio has 112.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ANAB a Buy, Sell or Hold?

AnaptysBio has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is AnaptysBio’s price target?

The average price target for AnaptysBio is 50.86. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $25.00. The average price target represents 112.80% Increase from the current price of $23.9.

What do analysts say about AnaptysBio?

AnaptysBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of ANAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AnaptysBio (ANAB) Stock Forecast & Price Target

ANAB Analyst Ratings

ANAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AnaptysBio

ANAB Analyst Recommendation Trends

ANAB Financial Forecast

ANAB Earnings Forecast

ANAB Sales Forecast

ANAB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts